Community built database about RNA / DNA or Peptide aptamers. The Aptamer Base is a collaborative knowledge base about aptamers, their interactions and detailed experimental conditions with citations to primary scientific literature. Aptamers are short single-stranded nucleic acids or amino acid polymers that recognize and bind to targets with high affinity and selectivity. Nucleic acid aptamers are typically isolated from large combinatorial libraries through the application of SELEX. For more information visit http://aptamerbase.semanticscience.org

The Aptamer Database is a comprehensive, annotated repository for information about aptamers and in vitro selection. This resource is provided to collect, organize and distribute all the known information regarding aptamer selection. Aptamers are DNA or RNA molecules that have been selected from random pools based on their ability to bind other molecules. Aptamers have been selected which bind nucleic acid, proteins, small organic compounds, and even entire organisms.

The summary of RMSD values at different time points throughout the MD simulation of the aptamer models corresponding to its crystal structures from the PDB database.

This thesis focuses on the development of DNA aptamers for exosome enrichment and biosensor establishment. The research includes the isolation of exosomes, selection of DNA aptamers with high affinity, and the application of these aptamers for enhanced exosome enrichment and detection. In addition, the aptamers are integrated with optical fiber technology to construct an aptamer–optical fiber biosensor, enabling the sensitive detection of exosomes and viral proteins. All experimental data generated throughout the study have been compiled into the accompanying dataset. This dataset contains raw data collected from various experiments, including gel electrophoresis, ELONA, western blot, and transmission electron microscopy (TEM), as well as processed data and analysis files, primarily generated using GraphPad Prism. All files are named and numbered according to the corresponding figures and experiments presented in the thesis. For access to specific data documents, please refer to the instructions provided in the README file.

This is the raw selection dataset generated by ProSELEX pipeline (https://www.nature.com/articles/s41557-023-01207-z). The target of selection is human myeloperoxidase (MPO). See https://github.com/dwangnu/AptaZ for instructions.

• The global industry was valued at US$ 219.9 Mn in 2023
• It is projected to advance at a CAGR of 17.2% from 2024 to 2034 and reach more than US$ 1.2 Bn by the end of 2034

Market Overview

Regional Outlook of Nucleic Acid Aptamers Industry

Nucleic Acid Aptamers Market Snapshot

The thesis is about the development of DNA aptamers-functionalized medicine for cartilage and bone regeneration applications. It includes the work of recombinant protein target expression, DNA aptamer selection, and application of aptamers for developing regenerative medicine. Data of this research were obtained from experimental and in-silica modeling analysis, which is compiled in the dataset.This dataset contains the raw data collected from experiments (e.g. gel electrophoresis, ELONA, EMSA, etc) and online database (e.g. https://www.rcsb.org/, etc), and data analysis files generated by different software (e.g. Origin, GraphPad, and Biovia Discovery Studio, etc). These data files are numbered as same as what they are named in the thesis. To get access to different data documents, please follow the instructions in the Readme file.

Human noroviruses (HuNoV) are the leading cause of acute viral gastroenteritis and an important cause of foodborne disease. Despite their public health significance, routine detection of HuNoV in community settings, or food and environmental samples, is limited, and there is a need to develop alternative HuNoV diagnostic reagents to complement existing ones. The purpose of this study was to select and characterize single-stranded (ss)DNA aptamers with binding affinity to HuNoV. The utility of these aptamers was demonstrated in their use for capture and detection of HuNoV in outbreak-derived fecal samples and a representative food matrix. SELEX (Systematic Evolution of Ligands by EXponential enrichment) was used to isolate ssDNA aptamer sequences with broad reactivity to the prototype GII.2 HuNoV strain, Snow Mountain Virus (SMV). Four aptamer candidates (designated 19, 21, 25 and 26) were identified and screened for binding affinity to 14 different virus-like particles (VLPs) corresponding to various GI and GII HuNoV strains using an Enzyme-Linked Aptamer Sorbant Assay (ELASA). Collectively, aptamers 21 and 25 showed affinity to 13 of the 14 VLPs tested, with strongest binding to GII.2 (SMV) and GII.4 VLPs. Aptamer 25 was chosen for further study. Its binding affinity to SMV-VLPs was equivalent to that of a commercial antibody within a range of 1 to 5 µg/ml. Aptamer 25 also showed binding to representative HuNoV strains present in stool specimens obtained from naturally infected individuals. Lastly, an aptamer magnetic capture (AMC) method using aptamer 25 coupled with RT-qPCR was developed for recovery and detection of HuNoV in artificially contaminated lettuce. The capture efficiency of the AMC was 2.5–36% with an assay detection limit of 10 RNA copies per lettuce sample. These ssDNA aptamer candidates show promise as broadly reactive reagents for use in HuNoV capture and detection assays in various sample types.

This dataset contains the 4 projects in the thesis titled "Electrochemical Aptamer Biosensors for Point-of-Care Diagnostics".The saliva COVID nucleocapsid (N) protein detection project describes the adaptation of 4 different N protein aptamers into electrochemical biosensing for COVID diagnosis using saliva samples.The Liquid-Liquid phase separation (LLPS) electrochemical aptamer biosensing project investigates COVID spike protein enrichment and improved electrochemical sensitivity in synthetic and serum biofluids.The methylene-blue (MB)-modified aptamer electrochemical sensing is a novel non-natural aptamer with intrinsic redox activity for CA19-9 pancreatic cancer diagnosis.The aptamer-OECT is the integration of organic electrochemical transistor into traditional electrochemical aptamer biosensing for enhanced analytical sensitivity against cortisol, insulin and spike protein.Each project folder includes the raw data files, excel logbook for analysis and Origin files for figures. Raw data files are allocated into separated subfolders according to the subtitles in each thesis chapter. Excel files record the data summary for all experiments described in the thesis. The Origin files summarize the data from each experiment to plot the figures presented in the thesis.

This dataset supports the discovery and characterization of two DNA aptamers, Bvd4 and Brb7, that selectively bind to the bile pigments biliverdin and bilirubin, respectively—metabolites derived from heme degradation. These pigments are clinically relevant biomarkers associated with conditions such as neonatal jaundice, liver dysfunction, and hemolysis. The aptamers identified in this study may also serve as molecular switches for regulating gene expression.

To support rigorous validation and reuse, the dataset includes raw experimental data obtained from: - Fluorescence titration assays using Thioflavin T (ThT) for binding curve generation. - Isothermal titration calorimetry (ITC) for thermodynamic profiling and dissociation constant (Kd) measurement. - Nuclear magnetic resonance (NMR) spectroscopy for structural validation and analysis of aptamer–ligand interactions. - UV–Vis spectroscopy for assessing pigment stability and monitoring bilirubin oxidation, - Sensor kinetic assays for evaluating real-time detection response and selectivity, and limit-of-detection (LOD) determination,

The tightest biliverdin aptamer exhibited a Kd of 6 nM and an LOD of 0.7 nM. A separate aptamer showed specific binding to bilirubin with a Kd of 203 nM and an LOD of 47 nM. These values were confirmed using multiple orthogonal techniques.

All experiments were conducted under controlled laboratory conditions at 25°C. Data are organized in tidy CSV format and correspond to Figures 3–8 and S1–S3 of the main article. Each file contains numeric measurements such as emission intensities, integrated heats, chemical shift data, and spectral information. This dataset facilitates further research into aptamer–target interactions, biosensor development, and nucleic acid-based sensing strategies for heme metabolites.

The global nucleic acid aptamers market is experiencing robust growth, driven by increasing demand for targeted therapeutics and diagnostic tools. The market, valued at approximately $2.5 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 15% from 2025 to 2033, reaching an estimated market value of $8 billion by 2033. This significant expansion is fueled by several key factors, including the rising prevalence of chronic diseases necessitating advanced treatment options, the growing adoption of aptamers in personalized medicine, and ongoing research and development efforts focused on enhancing aptamer efficacy and reducing production costs. The pharmaceutical segment currently dominates the application landscape, driven by the success of aptamers in drug delivery and targeted therapy development, however, the research sector is showing significant growth potential. DNA aptamers currently hold a larger market share compared to RNA aptamers due to their superior stability and ease of synthesis. However, RNA aptamers are gaining traction due to their potential for specific binding and therapeutic applications. Geographic growth is largely driven by North America and Europe, due to strong regulatory frameworks, robust healthcare infrastructure and a high concentration of pharmaceutical companies. However, the Asia-Pacific region is expected to witness the fastest growth, fueled by increasing healthcare expenditure and a growing focus on innovative therapeutic solutions. Geographic expansion and technological advancements within the nucleic acid aptamer field are expected to further drive market expansion. While challenges remain in terms of manufacturing scalability and regulatory approvals, continuous innovation and investment are actively addressing these hurdles. The emergence of novel aptamer technologies, including those focusing on improved selectivity and delivery mechanisms, promises to further propel market growth. The increasing collaboration between academic institutions, biotechnology companies and pharmaceutical giants is expected to significantly expedite the development and commercialization of novel aptamer-based products in the coming years. The competitive landscape is characterized by both established players and emerging companies contributing to the advancement of aptamer technologies and expansion into diverse therapeutic areas.

Target proteins and aptamers obtained from PDB database, which were applied for our model.

RNA aptamers are single-stranded nucleic acids of 20–100 nucleotides, with high sensitivity and specificity against particular molecular targets. In vitro production and selection of aptamers can be performed using the SELEX method. However, this procedure requires considerable time and cost. In this sense, bioinformatics tools play an important role in reducing the time and cost associated with development and production of aptamers. In this article, we propose bioinformatics strategies for modeling and analysis of the interaction with molecular targets for two RNA aptamers: ATP binding RNA aptamer and iSpinach aptamer. For this purpose, molecular modeling of the tertiary structure of the aptamers was performed with two servers (SimRNA and RNAComposer); and AutoDock Vina and rDock programs were used to dock their respective ligands. The predictions developed with these methods could be used for in silico design of RNA aptamers, through a simple and accessible methodology. Supplemental data for this article is available online at https://doi.org/10.1080/15257770.2021.1951754 .

APTAMD_Simulations.tar: Input files required for reproduccing the conventional molecular dynamics simulations reported in the article "Refinement and Truncation of DNA Aptamers based on Molecular Dynamics Simulations: Computational Protocol and Experimental Validation".

Fitting_echem_curves.opj: Data corresponding to binding curves organized in folders for each type of aptamers: a) Anti-collagen aptamers (data not shown, only K_D is given in table 1); b) Anti-PSA aptamers (figure 4A of the main text); c) Gli1 aptamers (figure 3A of the main text); d) PSA-1 aptamers (figure 3D of the main text). Each folder contains the spreadsheet with the aptamer concentrations assayed, the current measured in percentage (mean of three measurements) with the standard deviation and the fitting to the Hill or Langmuir model, and the corresponding graphs.

The files include the following:Calculation of BNR and R values in SELEX experiments for MutS and thrombinSource files for Figures used in the main text and SI (Origin and png files)Compilation of BNR gathered from SELEX experiments across diverse protein targets, sourced from the SELEX community

The Aptamer Development Services market is experiencing robust growth, driven by the increasing demand for targeted therapeutics and diagnostics. The market's expansion is fueled by several key factors, including the rising prevalence of chronic diseases necessitating advanced diagnostic and treatment options, the inherent advantages of aptamers over traditional antibodies (such as higher specificity, lower immunogenicity, and easier modification), and ongoing advancements in aptamer selection technologies, such as SELEX and microfluidic-based methods. Significant investments in research and development by both pharmaceutical companies and academic institutions are further bolstering market growth. While data limitations prevent precise quantification, a conservative estimate based on industry growth trends suggests a market value exceeding $500 million in 2025, with a compound annual growth rate (CAGR) projected to remain above 15% through 2033. This growth is expected across various segments, including therapeutic aptamer development, diagnostic aptamer development, and research services. The market is also witnessing the emergence of innovative applications such as aptamer-based biosensors and targeted drug delivery systems. Competition within the Aptamer Development Services market is intense, with numerous companies offering a range of services. Key players such as Profacgen, Creative Biolabs, and Aptagen are driving innovation through strategic partnerships, acquisitions, and the development of proprietary technologies. The geographical distribution of the market is likely skewed towards North America and Europe, given the concentration of research institutions and pharmaceutical companies in these regions. However, emerging economies in Asia-Pacific are also witnessing growing interest and investment in aptamer-based technologies, indicating a potential for future market expansion in these regions. Regulatory approvals and reimbursement policies will play a crucial role in shaping the market's trajectory in the coming years. The increasing adoption of aptamers in personalized medicine and point-of-care diagnostics is projected to further accelerate the market growth during the forecast period.

Biological Magnetic Resonance Bank Entry 26842: NMR resonance assignments for the tetramethylrhodamine binding RNA aptamer 3 in complex with the ligand 5-carboxy-tetramethylrhodamine

The aptamers market is anticipated to reach 291.6 million USD by 2033, exhibiting a 19% CAGR from 2025 to 2033. Aptamers, synthetic oligonucleotides that bind specific molecular targets with high affinity, are gaining traction due to their diverse applications, including research and development, drug discovery, diagnostics, and therapeutics. The rising prevalence of chronic diseases, increasing demand for personalized medicine, and advancements in molecular biology technologies drive the market's growth. The market is segmented by application and type. Research and development accounts for the largest share, driven by the increasing adoption of aptamers for target validation, drug screening, and biomarker discovery. Drug discovery is another key segment, with aptamers being used as therapeutic agents, diagnostic tools, and drug delivery vehicles. DNA-based aptamers dominate the market, followed by RNA-based aptamers. Regional analysis reveals that North America holds the largest market share, followed by Europe and Asia Pacific. Key players include TriLink BioTechnologies, AptaBharat, SomaLogic, AM Biotechnologies, Aptamer Sciences, Base Pair Biotechnologies, Aptamer Group, Aptagen, Aptus Biotech, NeoVentures Biotechnology, Ray Biotech, and Vivonics.

Protein-Protein, Genetic, and Chemical Interactions for Silwal AP (2022):A universal DNA aptamer as an efficient inhibitor against spike-protein/hACE2 interactions. curated by BioGRID (https://thebiogrid.org); ABSTRACT: A universal aptamer against spike-proteins of diverse SARS-CoV-2 variants was discovered via DNA SELEX towards the wild-type (WT) spike-protein. This aptamer, A1C1, binds to the WT spike-protein or other variants of concern such as Delta and Omicron with low nanomolar affinities. A1C1 inhibited the interaction between hACE2 and various spike-proteins by 85-89%. This universal A1C1 aptamer can be used to design diagnostic and therapeutic molecular tools to target SARS-CoV-2 and its variants.